This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Frindik, J. P.
Right arrow Articles by Baptista, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Frindik, J. P.
Right arrow Articles by Baptista, J.
Related Collections
Right arrow Endocrinology

PEDIATRICS Vol. 104 No. 4 Supplement October 1999, pp. 1000-1004

Adult Height in Growth Hormone Deficiency: Historical Perspective and Examples From the National Cooperative Growth Study

Received May 13, 1999; accepted Jun 22, 1999.

J. Paul Frindik* and Joyce BaptistaDagger

From the * Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, Arkansas; and Dagger  Medical Affairs, Genentech, Inc, South San Francisco, California.

There are few historical data on final or adult heights after the completion of long-term growth hormone (GH) therapy in children with GH deficiency (GHD). Adult height has been defined as that achieved at chronologic ages ranging from 18 to 30 years, at bone ages >= 13 years (girls) and >= 15 years (boys), at growth velocities <= 1 to 2 cm per 6 to 12 months, at the "cessation of growth," at "1 year after the completion of pubertal development," and that at which patients are either "satisfied with their height" or have attained an "accept adult stature."

Without GH treatment, children with GHD have a mean adult height standard deviation score of -4.7 (range, -6.1 to -3.9). After treatment, the standard deviation score range from -4.7 to -1.2 (pituitary GH [pitGH] 2-4 times a week) and from -1.4 to -0.5 (recombinant human [rhGH] GH 3 times a week to daily) in women and from -3.6 to -1.1 (pitGH) and from -1.3 to -0.7 (rhGH) in men. Because there is no uniformly applied definition of adult height, comparisons are difficult, but historical data suggest that posttreatment heights are greater with rhGH than with pitGH.

Using the National Cooperative Growth Study database, we found that the criteria used to define adult height affected the apparent outcome. When chronologic age >= 20 years for men and >= 18 years for women was the only criterion, 27% of patients grew >= 5 cm after having reached this age. Adding the requirement of advanced puberty before adult height could be considered to have been attained reduced the proportion of those who later grew >= 5 cm to <10%, but also decreased the number of patients available for analysis. A combination of criteria for adult height (chronologic and bone age >= 16 years for boys and >= 14 years for girls plus advanced puberty plus growth rate of <2 cm per year) left only 1% of patients with later growth of >= 5 cm.

 Key words:  adult height, growth hormone, growth hormone deficiency.




This article has been cited by other articles:


Home page
 Postgrad. Med. J.Home page
A J van der Lely
Justified and unjustified use of growth hormone
Postgrad. Med. J., October 1, 2004; 80(948): 577 - 580.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. Coutant, S. Rouleau, F. Despert, N. Magontier, D. Loisel, and J.-M. Limal
Growth and Adult Height in GH-Treated Children with Nonacquired GH Deficiency and Idiopathic Short Stature: The Influence of Pituitary Magnetic Resonance Imaging Findings
J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4649 - 4654.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
B. Kohn, J. R. Julius, and S. L. Blethen
Combined Use of Growth Hormone and Gonadotropin-releasing Hormone Analogues: The National Cooperative Growth Study Experience
Pediatrics, October 1, 1999; 104(4): 1014 - 1018.
[Abstract] [Full Text]